Table 1 Sociodemographic and clinical variables of the followed cohort (n = 797) stratified for outcomes of the study
Variable | Total sample followed (n = 797) | Return to Emergency Services (n = 160) | Readmission to hospital (n = 35) | Death after discharge (n = 8) |
|---|---|---|---|---|
N (%), x (s) | N (%), x (s) | N (%), x (s) | N (%), x (s) | |
Men | 428 (53.7) | 85 (53.1) | 15 (42.9) | 3 (37.5) |
Age: x (s) | 63.0 (14.4) | 61.7 (15.3) | 67.5 (16.9) | 82.1 (4.2) |
Age categories | ||||
<40 years | 45 (5.6) | 11 (6.9) | 2 (5.7) | 0 (0) |
40–50 years | 93 (11.7) | 20 (12.5) | 0 (0) | 0 (0) |
50–60 years | 181 (22.7) | 39 (24.4) | 8 (22.9) | 0 (0) |
60–70 years | 206 (25.8) | 43 (26.9) | 10 (28.6) | 0 (0) |
70–80 years | 164 (20.6) | 25 (15.6) | 6 (17.1) | 2 (25.0) |
80–90 years | 95 (11.9) | 16 (10.0) | 5 (14.3) | 6 (75.0) |
>90 years | 13 (1.6) | 6 (3.8) | 4 (11.4) | 0 (0) |
Setting | ||||
Granada | 361 (45.3) | 75 (46.9) | 18 (51.4) | 4 (50.0) |
Córdoba | 186 (23.3) | 40 (25.0) | 6 (17.1) | 1 (12.5) |
Cádiz | 27 (3.4) | 5 (3.1) | 0 (0) | 0 (0) |
Jaén | 223 (28.0) | 40 (25.0) | 11 (31.4) | 3 (37.5) |
Any comorbidity | 538 (67.5) | 104 (65.0) | 23 (65.7) | 7 (87.5) |
Hypertension | 409 (51.3) | 77 (48.1) | 18 (51.4) | 6 (75.0) |
Diabetes mellitus | 166 (20.8) | 35 (21.9) | 7 (20.0) | 1 (12.5) |
Cardiovascular disease | 164 (20.6) | 40 (25.0) | 13 (37.1) | 3 (37.5) |
Pneumopathy | 107 (13.4) | 22 (13.8) | 3 (8.6) | 2 (25.0) |
COPD | 40 (5.0) | 7 (4.4) | 1 (2.9) | 1 (12.5) |
Asthma | 59 (7.4) | 11 (6.9) | 1 (2.9) | 0 (0) |
Chronic kidney disease | 69 (8.7) | 14 (8.8) | 5 (14.3) | 3 (37.5) |
Autoimmune disease | 61 (7.7) | 17 (10.6) | 2 (5.7) | 1 (12.5) |
Immunosuppression | 36 (4.5) | 10 (6.3) | 2 (5.7) | 0 (0) |
Active neoplasm | 32 (4.0) | 6 (3.8) | 1 (2.9) | 1 (12.5) |
Polymedicationa | 295 (37.0) | 68 (42.5) | 20 (57.1) | 6 (75.0) |
Dependence | 120 (15.1) | 29 (18.1) | 14 (40.0) | 5 (62.5) |
Living at home | 712 (89.3) | 138 (86.3) | 24 (68.7) | 5 (62.5) |
Hospitalization days x (s) | 15.0 (13.5) | 16.6 (13.8) | 22.3 (20.0) | 19.4 (12.3) |
Ferritin at admission x (s) | 685.0 (952.2) | 537.1 (546.5) | 378.8 (308.5) | 372.8 (502.9) |
Unknown | 108 (13.6) | 23 (14.4) | 4 (11.4) | 1 (12.5) |
Abnormal TR at admission | 667 (83.7) | 128 (80.0) | 23 (65.7) | 7 (87.5) |
Unknown | 36 (4.5) | 8 (5.0) | 3 (8.6) | 0 (0) |
CRS | 298 (37.4) | 55 (34.4) | 11 (31.4) | 2 (25.0) |
Unknown | 62 (7.8) | 13 (8.1) | 3 (8.6) | 0 (0) |
Concomitant infectionb | 111 (13.9) | 29 (18.1) | 9 (25.7) | 1 (12.5) |
CURB-65 | ||||
0 | 221 (27.7) | 45 (28.1) | 4 (11.4) | 0 (0) |
1 | 241 (30.2) | 44 (27.5) | 9 (25.7) | 1 (12.5) |
2 | 130 (16.3) | 28 (17.5) | 10 (28.6) | 5 (62.5) |
3 | 21 (2.6) | 6 (3.8) | 1 (2.9) | 0 (0) |
4 | 2 (0.3) | 0 (0) | 0 (0) | 0 (0) |
Unknown | 182 (22.8) | 37 (23.1) | 11 (31.4) | 2 (25.0) |
Not candidate for CPR | 138 (17.3) | 31 (19.4) | 11 (31.4) | 5 (62.5) |
Unknown | 221 (27.7) | 37 (23.1) | 11 (31.4) | 2 (25.0) |
Hydroxychloroquine | 704 (88.3) | 137 (85.6) | 26 (74.3) | 5 (62.5) |
Lopinavir/ritonavir | 488 (61.2) | 94 (58.8) | 21 (60.0) | 1 (12.5) |
Azithromycin | 603 (65.7) | 117 (73.1) | 24 (68.6) | 4 (50.0) |
Corticosteroid boluses | 285 (35.8) | 60 (37.5) | 11 (31.4) | 3 (37.5) |
Tocilizumab | 82 (10.3) | 18 (11.3) | 6 (17.1) | 1 (12.5) |
Antibiotics | 477 (59.8) | 99 (61.9) | 21 (60.0) | 3 (37.5) |
ACEI/ARA-II | 221 (27.7) | 43 (26.9) | 12 (34.3) | 4 (50.0) |
ICU admission | 81 (10.8) | 16 (10.0) | 3 (8.6) | 0 (0) |
Total | 797 (100) | 160 (20.1) | 35 (4.4) | 8 (1.0) |